Spencer Guthrie

Outlook Android Flutter Python SharePoint

biotechnology research pan-amyloid removal par therapeutics amyloid diagnostics systemic amyloidosis toxic amyloid removal amyloid imaging agent i-124 evuzamitide pet imaging for amyloidosis neurodegenerative diseases attr amyloidosis al amyloidosis hereditary amyloidosis wild-type attr biologics for amyloidosis oral therapeutics for amyloidosis clinical trials for amyloidosis immune-mediated phagocytosis macrophage targeting non-invasive imaging fda orphan drug designation early diagnosis of amyloidosis amyloid deposition in organs diagnostic imaging for cardiac amyloidosis biopharmaceutical solutions pioneering research in amyloidosis transformative medicine therapeutic candidates for amyloidosis novel biologics proprietary technology acute heart failure disease-modifying therapies plasma cell targeting clinical advancement patient outcomes improvement diagnostic accuracy in amyloidosis therapeutic efficacy diagnosing cardiac amyloidosis multimodal imaging biotherapeutic development systemic amyloid diseases innovative treatments for amyloidosis amyloid-induced organ damage clinical data for amyloidosis pediatric amyloidosis community screening for amyloidosis early intervention strategies investigational drugs for amyloidosis treatment reversal of amyloidosis patient-centered care unmet medical needs in amyloidosis